Neuropsychopharmacology Reports最新文献

{"title":"Symptom-Domain Correlates of Self-Reported Anxious Distress in Outpatients With Major Depressive Disorder.","authors":"Shinpei Oga, Norio Sugawara, Yasushi Kawamata, Tomohiro Asahi, Yujin Ono, Sakurako Suzuki, Rina Hiramatsu, Norio Yasui-Furukori","doi":"10.1002/npr2.70165","DOIUrl":"10.1002/npr2.70165","url":null,"abstract":"<p><strong>Aim: </strong>Anxious distress is common in major depressive disorder (MDD), but real-world data are limited on its burden and relationship to depressive symptom domains. This study examined the prevalence and symptom-domain correlates of self-reported anxious distress in MDD outpatients.</p><p><strong>Methods: </strong>This cross-sectional study used routinely collected questionnaire and clinical data from Dokkyo Medical University Hospital. Depressive severity was assessed using the Japanese version of the Quick Inventory of Depressive Symptomatology (QIDS-J). Anxious distress was assessed using five self-rated items aligned with the Clinically Useful Depression Outcome Scale-Anxious Distress (CUDOS-A) and DSM-5 framework. Of 309 respondents, the primary analytic cohort comprised 206 participants with QIDS-J total scores of 6 or higher and complete anxious-distress item data.</p><p><strong>Results: </strong>A lower anxious-distress threshold (at least two items scored > = 2) was met by 153 participants (74.3%), and a stringent threshold (at least two items scored > = 3) by 85 (41.3%). QIDS-J total score correlated with anxious-distress burden (r = 0.614 for > = 2 count, r = 0.669 for > = 3 count, and r = 0.697 for summed score; all p < 0.001). In forced-entry Poisson models, sad mood, negative self-view, and psychomotor symptoms were associated with anxious-distress burden. Post hoc decomposition suggested that this psychomotor association was driven mainly by psychomotor agitation rather than retardation.</p><p><strong>Conclusion: </strong>Self-reported anxious distress was common among MDD outpatients and was closely associated with depressive severity and specific symptom domains, supporting further evaluation of anxious distress as a clinically relevant psychopathological dimension in MDD.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70165"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13534557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148874980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol Consumption Index as a Novel Risk Marker for Hypertension.","authors":"Ichiro Wakabayashi","doi":"10.1002/npr2.70166","DOIUrl":"10.1002/npr2.70166","url":null,"abstract":"<p><strong>Objectives: </strong>Habitual alcohol consumption is a risk factor for hypertension. The alcohol consumption index (ACI), which is defined as the product of mean corpuscular volume, gamma-glutamyl transferase, and high-density lipoprotein cholesterol levels in blood, has been proposed as a biomarker for estimating individual alcohol consumption. The aim of this study was to clarify the relationship between ACI and blood pressure.</p><p><strong>Methods: </strong>The participants were an occupational cohort consisting of 6 655 men (median age: 51 years). A retrospective cohort study was performed to compare variables at baseline of the study and 5 years later. The participants were categorized by frequency of alcohol intake as non-, occasional, or regular drinkers and by amount of average daily alcohol consumption as non-, light, or heavy drinkers. They were also classified into three tertiles according to ACI.</p><p><strong>Results: </strong>The odds ratios for incident hypertension in regular drinkers vs. nondrinkers [1.71 (95% confidence interval: 1.42 ~ 2.06)], heavy drinkers vs. nondrinkers [1.95 (1.60 ~ 2.37)], and the 3rd vs. 1st tertiles of ACI [1.81 (1.51 ~ 2.16)] were significantly higher than the reference level. The odds ratio for incident hypertension in the 3rd vs. 1st tertiles of ACI remained significant even after adjusting for blood pressure at baseline. In groups of individuals who changed after the 5-year follow-up from regular or heavy drinkers to nondrinkers and from the 3rd tertile of ACI to the 1st tertile, systolic and diastolic blood pressure levels were significantly lower after the follow-up than at baseline.</p><p><strong>Conclusion: </strong>ACI, as well as alcohol intake, was associated with the risk of hypertension. Decreases in ACI and alcohol consumption after the 5-year follow-up were associated with reductions in blood pressure. These findings suggest that ACI is a useful biomarker of alcohol-related hypertension.</p><p><strong>Tweetable abstract: </strong>The alcohol consumption index (ACI), defined as the product of GGT, HDL, and MCV, is associated with blood pressure and incident hypertension and may be a useful biomarker for prevention of alcohol-induced hypertension.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70166"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13563496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148945355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trial-History Effects During WCST in Treatment-Resistant Schizophrenia.","authors":"Ryo Sawagashira, Atsuhito Toyomaki, Hayato Watanabe, Naoki Hashimoto, Takahiro A Kato","doi":"10.1002/npr2.70151","DOIUrl":"10.1002/npr2.70151","url":null,"abstract":"<p><strong>Aim: </strong>Treatment-resistant schizophrenia (TRS) is a clinically important subtype of schizophrenia, but its cognitive characteristics remain incompletely understood. The Wisconsin Card Sorting Test (WCST) is widely used to assess executive dysfunction in schizophrenia, although conventional summary analyses may overlook trial-by-trial behavioral adaptation. This study aimed to examine whether recent trial outcome modulates subsequent responding differently between TRS and non-TRS patients during the WCST.</p><p><strong>Methods: </strong>We analyzed WCST data from 41 outpatients with schizophrenia, including 13 patients with TRS and 28 with non-TRS. Conventional subject-level indices, including perseveration rate and outcome-dependent reaction time (RT) adjustment, were first compared between groups. We then performed trial-level linear mixed-effects analyses using log-transformed RT as the dependent variable, with previous trial correctness, treatment resistance, their interaction, age, and sex as fixed effects. Additional sensitivity analyses included models with by-subject random slopes for previous trial correctness and analysis in an age-matched sample.</p><p><strong>Results: </strong>Conventional summary analyses showed no significant group differences in perseveration rate or RT measures. In the primary model, previous trial correctness significantly modulated subsequent RT, and the interaction between previous trial correctness and TRS suggested a group difference in outcome-dependent RT modulation. Specifically, the RT difference between trials following error and correct responses appeared smaller in TRS patients than in non-TRS patients. However, sensitivity analyses using by-subject random slopes and an age-matched sample showed similar directions and magnitudes of the interaction but did not reach statistical significance.</p><p><strong>Conclusion: </strong>Conventional WCST summary analyses did not distinguish TRS from non-TRS patients, whereas trial-level modeling provided preliminary evidence for possible alteration of outcome-dependent response adjustment in TRS. These findings suggest that dynamic behavioral phenotypes may provide a useful complement to standard neuropsychological indices in characterizing cognitive heterogeneity in schizophrenia, but replication in larger samples is needed.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70151"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serial Fetal Heart Rate Monitoring During Electroconvulsive Therapy in Late Pregnancy: A Case Report of Transition From Succinylcholine to Rocuronium Reversed With Neostigmine.","authors":"Katsuichiro Shimizu, Hiroyuki Muraoka, Tomoe Fujita, Kyoko Hattori, Taiyo Nishikawa, Hana Uchitsubo, Daigo Ochiai, Shunsuke Hyuga, Ken Inada","doi":"10.1002/npr2.70159","DOIUrl":"10.1002/npr2.70159","url":null,"abstract":"<p><p>Electroconvulsive therapy (ECT) is considered relatively safe and effective for severe psychiatric disorders during pregnancy, but evidence regarding neuromuscular blockers for ECT in pregnancy remains limited. We report a 30-year-old primigravida admitted at 30 weeks of gestation with severe major depressive disorder and persistent suicidal ideation despite pharmacotherapy. ECT was initiated at 32 weeks and 2 days of gestation. The first five sessions used succinylcholine. Owing to a nationwide shortage in Japan, the muscle relaxant was switched to rocuronium from the sixth session, with neostigmine and atropine used for reversal during the two antepartum rocuronium sessions. Serial cardiotocographic monitoring before and after each of the seven antepartum ECT sessions showed a transient decrease in fetal heart rate variability after ECT in all sessions and a transient increase in fetal heart rate baseline in five of the seven sessions (Sessions 1, 2, 3, 5, and 7), while fetal well-being was maintained throughout. Spontaneous vaginal delivery occurred at 37 weeks and 0 days, five days after the seventh ECT session. The infant developed respiratory failure shortly after birth and required ventilatory support for two days, but subsequently recovered without complications. Postpartum ECT was resumed for five additional sessions using rocuronium reversed with sugammadex, and the patient achieved clinical remission. This case suggests the feasibility of rocuronium with neostigmine reversal as an alternative to succinylcholine for ECT during late pregnancy when succinylcholine is unavailable, provided that multidisciplinary management and fetal monitoring are available.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70159"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13539057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148881136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The rs10781468 Genetic Polymorphism of the Gαq (GNAQ) Gene Is Associated With Responsiveness to Opioid Analgesics in Patients With Postoperative and Cancer Pain: An Exploratory Study.","authors":"Hiroaki Owada, Daisuke Nishizawa, Tsutomu Mieda, Miki Tsujita, Hideyuki Nakagawa, Shigeki Yamaguchi, Rikuhei Tsuchida, Yaeko Yokoshima, Akira Kitamura, Masakazu Hayashida, Ken-Ichi Fukuda, Tatsuya Ichinohe, Kazutaka Ikeda, Makoto Kurano, Masahiko Sumitani, Kanji Uchida","doi":"10.1002/npr2.70148","DOIUrl":"10.1002/npr2.70148","url":null,"abstract":"<p><strong>Background: </strong>G protein-coupled receptors, the largest class of cell surface receptors, are ubiquitously expressed throughout the body. Different subtypes of G protein α subunits activate distinct intracellular signaling pathways and mediate opioid analgesic effects. However, the contributions of these Gα subunits remain unclear. We conducted a hypothesis-generating, two-stage candidate gene association study to identify potential genetic loci related to pain processing and opioid analgesia, focusing on genes encoding G protein α subunits.</p><p><strong>Methods: </strong>To identify candidate single-nucleotide polymorphisms (SNPs) in seven genes encoding G protein α subunits, we analyzed postoperative opioid consumption, pain intensity, and opioid responsiveness in two exploratory cohorts [laparoscopy-assisted colectomy (n = 350) and mandibular plastic surgery (n = 354)]. For identified candidate SNPs, we further evaluated opioid responsiveness in a confirmatory cohort of 89 patients with cancer pain. We also conducted a preliminary sensitivity analysis adjusting for relevant covariates.</p><p><strong>Results: </strong>Two SNPs (rs10781468 in the GNAQ gene and rs308049 in the GNA11 gene) showed significant associations in both exploratory cohorts. Patients with postoperative pain who were homozygous for the minor allele of rs10781468 exhibited higher opioid sensitivity or lower pain severity. In the confirmatory cohort, homozygosity for the major allele of rs10781468 was significantly associated with increased opioid sensitivity for cancer pain management under the dominant model (p = 0.025) and the genotypic model (p = 0.020), whereas rs308049 was not. The observed phenotypes and associated genetic models differed across cohorts, and sensitivity analyses continued to demonstrate some significant associations.</p><p><strong>Conclusions: </strong>As a hypothesis-generating investigation, we suggest that rs10781468 may serve as a potential candidate marker of responsiveness to opioid analgesics. Our findings should be validated in a large-scale study with a homogeneous pain type in which the opioid administration protocol is controlled to further examine the association observed in this exploratory study.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70148"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148352724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Participant Satisfaction and Self-Reported Clinical Practice Behaviors in a Nationwide Guideline Education Program.","authors":"Kazuhiko Yamamuro, Kenta Ide, Yusuke Arai, Hiroyuki Muraoka, Toru Horinouchi, Yasushi Kawamata, Keisuke Mori, Shinichiro Ochi, Takashi Tsuboi, Hirotaka Yamagata, Hitoshi Iida, Yuka Yasuda, Junya Matsumoto, Naoki Hashimoto, Kazutaka Ohi, Toshiaki Onitsuka, Hisashi Yamada, Shusuke Numata, Hikaru Hori, Ken Inada, Koichiro Watanabe, Norio Yasui-Furukori, Ryota Hashimoto","doi":"10.1002/npr2.70147","DOIUrl":"10.1002/npr2.70147","url":null,"abstract":"<p><strong>Background: </strong>Educational interventions are widely used to promote guideline-concordant psychiatric practice. However, it remains unclear whether participants' subjective satisfaction translates into actual changes in clinical behavior (CB). This study examined the association between subjective assessment (SA) scores of the EGUIDE training programs for schizophrenia and major depressive disorder (MDD) and CB.</p><p><strong>Methods: </strong>In this multicenter observational study, we analyzed data from psychiatrists who participated in the EGUIDE training program. SA scores were obtained immediately after training using standardized questionnaires assessing satisfaction with program content, knowledge, skills, and future clinical intentions. CB was evaluated using self-report measures of guideline-concordant practice in general, schizophrenia-specific, and MDD-specific domains. Associations between SA and CB scores were examined using Spearman's rank correlation coefficients.</p><p><strong>Results: </strong>A total of 1399 psychiatrists were included in the analysis. The comprehensive SA score showed a significant positive correlation with the comprehensive CB score (r = 0.19, p < 0.001). Likewise, schizophrenia- and MDD-specific SA scores were positively correlated with all CB domains, including general guideline use and disorder-specific practices (ρ = 0.14-0.19, all p < 0.001). Although effect sizes were small, the associations were consistent across disorders and clinical domains.</p><p><strong>Conclusions: </strong>Higher satisfaction with guideline-based educational programs was associated with greater self-reported guideline-concordant CBs, suggesting that positive educational experiences may support improvements in psychiatric practice at the national level.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70147"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13368702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148448340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clobazam and Valproate, but Lamotrigine, a Sodium Channel Inhibitor, Reduce the Incidence of Hyperthermia-Induced Clonic Seizures in Dravet Syndrome Mice: Assessment of Anti-Seizure Effects in Mice Using a Stabilized Ambient Temperature System.","authors":"Futa Sato, Mayuka Nakamura, Megumi Oishi, Yuki Matsuo, Naoki Amada, Takashi Wadatsu, Nobuyoshi Jinnai, Yusuke Kakumoto, Kenji Maeda, Yuki Yamasaki, Takashi Futamura","doi":"10.1002/npr2.70168","DOIUrl":"10.1002/npr2.70168","url":null,"abstract":"<p><strong>Background: </strong>Dravet syndrome (DS) is a severe and treatment-resistant epileptic encephalopathy, most commonly caused by de novo mutations in the sodium voltage-gated channel alpha subunit 1 (SCN1A) gene. Patients with DS often present with febrile seizures. It has been reported that Scn1a mutant mice have the risk for hyperthermia-induced clonic seizures similar to those observed in patients with DS. Using our heating protocol with an incubator, we evaluated the effects of antiseizure medications on the incidence of hyperthermia-induced clonic seizures in mutant Scn1a knock-in (KI)/+ mice.</p><p><strong>Methods: </strong>For clonic seizure induction in Scn1a KI/+ mice, each mouse was placed into an incubator (38°C-40°C) and observed for 15 min. Antiseizure medications were administered orally 30 min prior to the experiment. The time to seizure onset and the incidence of clonic seizures were analyzed to evaluate and compare the antiseizure effects among treatment groups.</p><p><strong>Results: </strong>Our incubation system increased the body temperature of mice and induced clonic seizures in Scn1a KI/+ mice. Clobazam (CLB) and valproate (VPA) significantly reduced the incidence of hyperthermia-induced clonic seizures in Scn1a KI/+ mice, with 50% effective dose (ED₅₀) values of 1.94 mg/kg (95% confidence interval [CI]: 0.93-3.89 mg/kg) and 255.87 mg/kg (95% CI: 188.66-356.85 mg/kg) respectively, and prolonged the time to seizure onset. In contrast, lamotrigine (LTG), a sodium channel blocker, did not reduce the incidence of hyperthermia-induced seizures. CLB and LTG did not affect the body temperature. VPA decreased the body temperature compared to the vehicle-treated mice before and after incubation.</p><p><strong>Conclusion: </strong>These results reflect clinical findings that CLB and VPA suppress, but LTG does not suppress seizures in patients with DS. Our data demonstrate the validity of our test system to induce hyperthermia-induced seizures and to evaluate the efficacy of antiseizure medications in Scn1a KI/+ mice.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70168"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13577812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Affective Temperaments With One-Year Depressive Outcomes in Middle-Aged and Older Patients With Mood Disorders Without Psychiatric Comorbidities.","authors":"Takashi Ozaki, Hisashi Narita, Shizuka Mito, Niki Udo, Nobuyuki Mitsui, Naoki Hashimoto, Ichiro Kusumi, Takahiro A Kato","doi":"10.1002/npr2.70170","DOIUrl":"10.1002/npr2.70170","url":null,"abstract":"<p><strong>Aim: </strong>The course of depressive symptoms in mood disorders may be influenced by multiple clinical factors, making predictors of subsequent symptoms difficult to identify. This study examined whether affective temperaments are associated with depressive symptoms at one-year follow-up in middle-aged and older patients with mood disorders without clinically relevant psychiatric comorbidities.</p><p><strong>Methods: </strong>This one-year longitudinal observational study included 91 patients aged 40-75 years with major depressive disorder (MDD) or bipolar disorder (BD) who were admitted to Hokkaido University Hospital for a recent major depressive episode, completed baseline assessments at discharge, and were followed for 1 year after discharge. Patients with clinically relevant psychiatric comorbidities were excluded. Affective temperaments were assessed using the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire. Multiple linear regression analyses were performed to examine factors associated with the 17-item Hamilton Depression Rating Scale (HAM-D17) total score at one-year follow-up, and logistic regression analyses to examine factors associated with subthreshold or more severe depressive symptoms at one-year follow-up. Temperament-by-diagnosis interaction analyses were performed to examine whether these associations differed between MDD and BD. This study was approved by the ethics committee of Hokkaido University Hospital.</p><p><strong>Results: </strong>Depressive and cyclothymic temperaments were significantly associated with a higher HAM-D17 total score at one-year follow-up after adjustment. Depressive temperament was also associated with non-remission. A significant cyclothymic temperament-by-diagnosis interaction was observed.</p><p><strong>Conclusion: </strong>Depressive and cyclothymic temperaments may be clinically relevant for understanding residual depressive symptoms at one-year follow-up in middle-aged and older patients with mood disorders without clinically relevant psychiatric comorbidities. The significant cyclothymic temperament-by-diagnosis interaction highlights the potential diagnosis-specific relevance of affective temperament. Larger prospective studies are required to confirm these findings.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70170"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder.","authors":"Arushika Aggarwal, Simon Erridge, Madhur Varadpande, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren","doi":"10.1002/npr2.70146","DOIUrl":"10.1002/npr2.70146","url":null,"abstract":"<p><strong>Introduction: </strong>Autism spectrum disorder (ASD) is a neurodevelopmental disorder associated with distressed behaviors and psychological challenges. This study aims to evaluate the change in health-related quality of life (HRQoL), anxiety, and sleep quality in autistic individuals prescribed cannabis-based medicinal products (CBMPs).</p><p><strong>Method: </strong>This observational case series analyzed data from the UK Medical Cannabis Registry on autistic adults treated with CBMPs. Demographic and clinical data were collected at baseline, with patient-reported outcome measures assessed up to 18 months. Primary outcomes included changes in anxiety (GAD-7), sleep quality (SQS), and HRQoL (EQ-5D-5L). Secondary outcomes included the incidence of adverse events. Statistical significance was indicated by p < 0.050.</p><p><strong>Results: </strong>One-hundred and thirty individuals met the inclusion criteria. GAD-7 (p < 0.001) and SQS (p < 0.001) scores improved from baseline to 18 months. EQ-5D-5L index values showed improvement from baseline (0.43 ± 0.30) to 18 months (0.51 ± 0.32, p < 0.001), and PGIC scores increased from 1 month (5.43 ± 1.49) to 18 months (5.65 ± 1.32, p = 0.013). Twenty-five participants (19.23%) reported a total of 232 (178.46%) adverse events, with most being mild (n = 88; 67.69%) or moderate (n = 99; 76.15%).</p><p><strong>Conclusion: </strong>Treatment with CBMPs was associated with improvements in HRQoL, anxiety, and sleep outcomes in autistic patients over an 18-month period. Given the absence of a control group, these findings represent associations rather than proven treatment effects. Further high-quality randomized controlled trials are needed to confirm the long-term efficacy and safety of CBMPs in ASD.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70146"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13323844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep Deprivation and Neuronal Hyperexcitation Share Transcriptomic Signatures.","authors":"Markos Michail Chatzigiannis, Hideo Hagihara, Tsuyoshi Miyakawa","doi":"10.1002/npr2.70150","DOIUrl":"10.1002/npr2.70150","url":null,"abstract":"<p><p>Although sleep deprivation (SD) is clinically associated with numerous neuropsychiatric disorders, its underlying molecular correlates remain unclear. Because extended wakefulness is accompanied by increased neuronal activity and network firing, SD may be associated with a hyperactive neural state. This study aimed to test the hypothesis that SD shares transcriptomic signatures induced by neuronal hyperexcitation and to identify the gene pathways and cell types associated with these signatures. Publicly available transcriptomic datasets were analyzed, including 32 SD and 23 neuronal hyperexcitation transcriptomic datasets. These datasets were systematically compared using the Running Fisher algorithm across multiple mouse brain regions and rodent neuronal hyperexcitation models. The analysis revealed significant positive transcriptomic overlaps between SD and neuronal hyperexcitation models (p ≤ 0.05 in 73% of cross-model comparisons). In addition, neuronal hyperexcitation datasets collected within 1-12 h after seizure induction showed stronger transcriptomic similarity to SD than those collected 24 h or later. The shared transcriptomic signature was significantly enriched for pathways associated with neuronal plasticity, immune response, and inflammation. Key overexpressed genes common to both conditions included immediate early genes (IEGs) such as Egr1, Fos, and Arc, as well as inflammation-associated genes such as Ptgs2 and Junb. Comparisons between SD single-cell and neuronal hyperexcitation datasets indicated that the shared signature was most strongly enriched in microglia and neurons, with additional contributions from endothelial cells and astrocytes. Microglia showed enrichment of stress- and immune-response genes, neurons exhibited IEG and plasticity-related signatures, and endothelial cells expressed metabolism-associated genes. Together, these findings indicate that SD is associated with a transcriptomic state resembling acute neuronal hyperexcitation, characterized by activation of neuronal plasticity-, neuroinflammatory-, and metabolism-related pathways. This shared molecular signature provides a transcriptomic framework linking sleep loss to molecular processes implicated in neuropsychiatric disorders and suggests that acute neuronal hyperexcitation-related molecular processes may contribute to SD-associated brain dysfunction.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"46 3","pages":"e70150"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13318531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}